Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. raised its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 33.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 545,658 shares of the specialty pharmaceutical company's stock after purchasing an additional 136,870 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.99% of Supernus Pharmaceuticals worth $19,731,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in SUPN. Barclays PLC lifted its position in shares of Supernus Pharmaceuticals by 88.3% during the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock valued at $3,393,000 after acquiring an additional 51,005 shares during the period. Franklin Resources Inc. lifted its position in shares of Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock valued at $987,000 after acquiring an additional 2,121 shares during the period. Empowered Funds LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter valued at approximately $1,498,000. Smartleaf Asset Management LLC lifted its position in shares of Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after acquiring an additional 870 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of Supernus Pharmaceuticals by 40.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company's stock valued at $7,901,000 after acquiring an additional 73,118 shares during the period.

Supernus Pharmaceuticals Stock Up 2.9%

Shares of Supernus Pharmaceuticals stock traded up $0.95 during trading on Friday, hitting $33.43. 548,988 shares of the company were exchanged, compared to its average volume of 489,907. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of 31.24 and a beta of 0.74. The firm has a 50 day moving average price of $31.88 and a 200 day moving average price of $34.84.

Analysts Set New Price Targets

SUPN has been the subject of a number of research reports. StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Insider Buying and Selling

In related news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. The trade was a 10.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 8.80% of the company's stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.